Visudyne for Subfoveal choroidal neovascularization (wet age-related macular degeneration)
Quick answer: Visudyne is used for Subfoveal choroidal neovascularization (wet age-related macular degeneration) as part of a photosensitizing agent (photodynamic therapy) treatment regimen. Verteporfin is activated by non-thermal red light to generate reactive oxygen species that occlude abnormal choroidal neovasculature The specific dosing for Subfoveal choroidal neovascularization (wet age-related macular degeneration) is determined by your prescriber based on individual factors.
Why is Visudyne used for Subfoveal choroidal neovascularization (wet age-related macular degeneration)?
Visudyne belongs to the Photosensitizing agent (photodynamic therapy) class. Verteporfin is activated by non-thermal red light to generate reactive oxygen species that occlude abnormal choroidal neovasculature This action makes it useful for treating or managing Subfoveal choroidal neovascularization (wet age-related macular degeneration) in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Visudyne is the right choice for a specific patient depends on the type and severity of Subfoveal choroidal neovascularization (wet age-related macular degeneration), response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Subfoveal choroidal neovascularization (wet age-related macular degeneration)
Common adult dosing range: 6 mg/m² IV infusion followed by laser activation. The actual dose for Subfoveal choroidal neovascularization (wet age-related macular degeneration) depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Visudyne medicine page.
What to expect
Visudyne treatment for Subfoveal choroidal neovascularization (wet age-related macular degeneration) typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Subfoveal choroidal neovascularization (wet age-related macular degeneration)
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Visudyne is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Photosensitizing agent (photodynamic therapy) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Visudyne
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Visudyne full prescribing information · All Photosensitizing agent (photodynamic therapy) alternatives
Frequently asked questions
How effective is Visudyne for Subfoveal choroidal neovascularization (wet age-related macular degeneration)?
Effectiveness varies by individual response, dose, and severity. Visudyne is one of several treatment options for Subfoveal choroidal neovascularization (wet age-related macular degeneration), supported by clinical evidence within the photosensitizing agent (photodynamic therapy) class. Discuss expected response with your prescriber.
How long do I need to take Visudyne for Subfoveal choroidal neovascularization (wet age-related macular degeneration)?
Treatment duration depends on the nature of Subfoveal choroidal neovascularization (wet age-related macular degeneration) — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Visudyne when used for Subfoveal choroidal neovascularization (wet age-related macular degeneration)?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Visudyne for Subfoveal choroidal neovascularization (wet age-related macular degeneration)?
Yes. Multiple medicines and non-drug options exist for Subfoveal choroidal neovascularization (wet age-related macular degeneration). Alternatives within the photosensitizing agent (photodynamic therapy) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.